RAdiation ComBined with BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT) Study: a Phase I/II Study of AMG757 / Tarlatamab and Concurrent Radiation Therapy in Tumors with High Prevalence of DLL3
Latest Information Update: 15 Mar 2025
At a glance
- Drugs Tarlatamab (Primary)
- Indications Bladder cancer; Carcinoma; Cervical cancer; Glioblastoma; Lung cancer; Malignant melanoma; Medullary thyroid cancer; Merkel cell carcinoma; Neuroblastoma; Neuroendocrine carcinoma; Non-small cell lung cancer; Solid tumours; Testicular cancer
- Focus Adverse reactions
- Acronyms RABBIT
Most Recent Events
- 13 Feb 2025 New trial record